PTGS2 and glioblastoma: Several in vitro studies have described the ability of the selective COX-2 inhibitors to improve GBM sensitiveness to traditional chemo- and radiotherapy, increasing cell death and apoptosis and reducing tumor migration and stemness potential [20,21,22].